Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-ZAP: Adjuvant Docetaxel + Zoledronic Acid in Prostate Cancer
NCT00258765Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2006
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zoledronic acid in prostate cancer (PCa), sponsored by Novartis. Started May 2006; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00258765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258765.